Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

被引:147
作者
Rojas, Camilo [1 ]
Thomas, Ajit G. [1 ]
Alt, Jesse [1 ]
Stathis, Marigo [1 ]
Zhang, Jie [2 ]
Rubenstein, Edward B.
Sebastiani, Silvia [3 ]
Cantoreggi, Sergio [4 ]
Slusher, Barbara S. [1 ]
机构
[1] Johns Hopkins Univ, Brain Sci Inst, Neurotranslat Ctr, Sch Med, Baltimore, MD 21224 USA
[2] Profectus Biosci, Baltimore, MD USA
[3] Helsinn Healthcare SA, Business Unit Oncol & Canc Support Care, Lugano, Switzerland
[4] Helsinn Healthcare SA, Res & Dev, Lugano, Switzerland
关键词
5-HT3; receptor; Palonosetron; Granisetron; Ondansetron; Receptor internalization; CHEMOTHERAPY-INDUCED NAUSEA; MODERATELY EMETOGENIC CHEMOTHERAPY; PHASE-III TRIAL; DOUBLE-BLIND; ANTAGONIST; BINDING; LIGAND; CELLS; GRANISETRON; ONDANSETRON;
D O I
10.1016/j.ejphar.2009.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Palonosetron is a 5-HT3 receptor antagonist that has demonstrated superiority in preventing both acute and delayed emesis when compared to older first generation 5-HT3 receptor antagonists. The objective of this work was to determine if palonosetron exhibits unique molecular interactions with the 5-HT3 receptor that could provide a scientific rationale for observed clinical efficacy differences. Previously, we showed that palonosetron exhibits allosteric binding and positive cooperativity to the 5-HT3 receptor in contrast to ondansetron and granisetron which exhibit simple bimolecular binding. The present work shows, through several independent experiments, that palonosetron uniquely triggers 5-HT3 receptor internalization and induces prolonged inhibition of receptor function. After 24 h incubation followed by dissociation conditions, [H-3]palonosetron remained associated with whole cells but not to cell-free membranes (p<0.001). [H-3] Palonosetron's binding to cells was resistant to both protease and acid treatments designed to denature cell surface proteins suggesting that the receptor complex was inside the cells rather than at the surface. Cells pretreated with unlabeled palonosetron subsequently exhibited reduced cell surface 5-HT3 receptor binding. Palonosetron-triggered receptor internalization was visualized by confocal fluorescence microscopy using cells transfected with 5-HT3 receptor fused to enhanced cyan fluorescent protein. In contrast, granisetron and ondansetron showed minimal to no effect on receptor internalization or prolonged inhibition of receptor function. These experiments may provide a pharmacological basis for differences noted in published clinical trials comparing palonosetron to other 5-HT3 receptor antagonists. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 26 条
  • [1] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
    Aapro, M. S.
    Grunberg, S. M.
    Manikhas, G. M.
    Olivares, G.
    Suarez, T.
    Tjulandin, S. A.
    Bertoli, L. F.
    Yunus, F.
    Morrica, B.
    Lordick, F.
    Macciocchi, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (09) : 1441 - 1449
  • [2] [Anonymous], J SUPPORT ONCOL
  • [3] BONHAUS DW, 1995, J NEUROCHEM, V65, P104
  • [4] The pharmacological and functional characteristics of the serotonin 5-HT3A receptor are specifically modified by a 5-MT3B receptor subunit
    Dubin, AE
    Huvar, R
    D'Andrea, MR
    Pyati, J
    Zhu, JY
    Joy, KC
    Wilson, SJ
    Galindo, JE
    Glass, CA
    Luo, L
    Jackson, MR
    Lovenberg, TW
    Erlander, MG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) : 30799 - 30810
  • [5] Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron
    Eisenberg, P
    Figueroa-Vadillo, J
    Zamora, R
    Charu, V
    Hajdenberg, J
    Cartmell, A
    Macciocchi, A
    Grunberg, S
    [J]. CANCER, 2003, 98 (11) : 2473 - 2482
  • [6] Ligand-induced 5-HT3 receptor internalization in enteric neurons in rat ileum
    Freeman, Samara L.
    Glatzle, Jorg
    Robin, Carla S.
    Valdellon, Melissa
    Sternini, Catia
    Sharp, James W.
    Raybould, Helen E.
    [J]. GASTROENTEROLOGY, 2006, 131 (01) : 97 - 107
  • [7] Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? - Systematic re-evaluation of clinical evidence and drug cost implications
    Geling, O
    Eichler, HG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1289 - 1294
  • [8] GLENNON RA, 2008, FOYES PRINCIPLES MED, P434
  • [9] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    Gralla, R
    Lichinitser, M
    Van der Vegt, S
    Sleeboom, H
    Mezger, J
    Peschel, C
    Tonini, G
    Labianca, R
    Macciocchi, A
    Aapro, M
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577
  • [10] HAIGLER HT, 1980, J BIOL CHEM, V255, P1239